|


Applied Genomics has been acquired by Clarient Inc., a leading provider of cancer diagnostic testing.


AGI’s taxane
sensitivity marker, Mammotax, recently published in Breast
Cancer Research. Mammotax is a single antibody immunohistochemistry test for assessing whether a patient will respond to taxane therapy. A discovery and validation
study were
published in the March 23 issue of Breast
Cancer Research. AGI is currently evaluating Mammotax in several additional independent clinical cohorts.
|